Clinical and immunogenetic correlates of abacavir hypersensitivity.
A patch test (PT) may be useful in defining true abacavir hypersensitivity syndrome (AHS). Seven previously PT-positive patients remote from the original AHS were shown to have robust 24 h responses, supporting PT durability. HLA-B*5701 was present in all seven PT-positive versus one of 11 controls tolerating abacavir (P < 0.001). Five of seven PT (71%) versus one of 11 controls (9%) (P = 0.005) showed significant abacavir-specific CD8 proliferation, suggesting a direct role for HLA-B*5701-restricted CD8 cells in the pathophysiology of AHS.
Phillips
Elizabeth J
EJ
British Columbia Centre for Excellence in HIV/AIDS, Vancouver, University of British Columbia, Canada.
Wong
Gavin A
GA
Kaul
Rupert
R
Shahabi
Kamnoosh
K
Nolan
David A
DA
Knowles
Sandra R
SR
Martin
Annalise M
AM
Mallal
Simon A
SA
Shear
Neil H
NH
D019380:Anti-HIV Agents / Q000009:adverse effects*; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D015224:Dideoxynucleosides / Q000009:adverse effects*; D003875:Drug Eruptions / Q000175:diagnosis / Q000209:etiology* / Q000276:immunology; D020022:Genetic Predisposition to Disease; D015235:HLA-B Antigens / Q000032:analysis; D006801:Humans; D010328:Patch Tests / Q000379:methods; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects*; D000099227:Abacavir
D019380:Anti-HIV Agents; D015224:Dideoxynucleosides; D015235:HLA-B Antigens; D018894:Reverse Transcriptase Inhibitors; D000099227:Abacavir; C484830:HLA-B*57:01 antigen